Mr. Chair, this is the first opportunity I have had since becoming Minister of Health three months ago to formally address this honourable House. I must say that I am very pleased that it is on an issue of such importance. I am doubly pleased and impressed that hon. members have decided to come together to share ideas on the complex and emotional issue of hepatitis C in a non-partisan fashion.
For as long as I have been in public life it has been my view that we the elected legislators do our job best and Canadians are best served when we reason together constructively and respectfully. This is even more so when an issue is tough, when it evokes strong passions and when, as in the case of the suffering of victims who have been infected with hepatitis C through the blood system, it appeals on so many levels to that basic human compassion and decency which I know motivates all members in the House. This is the attitude that I bring to all of my duties as Minister of Health for Canada and it is the attitude that will shape my comments this evening.
As I said, I have been Minister of Health for a very short time but in that short time the issue before us tonight has impressed me deeply. I have heard from Canadians who have contracted hepatitis C through the blood supply. I have also heard from family members who have been touched by this tragedy and who are providing day to day support to their loved ones. It is hard not to be moved by their experiences and by their courage in moving forward.
This House has long been engaged on this issue, so I will not repeat all of the facts surrounding it, but I will say that from the very beginning our government has been moved both by compassion and a clear desire to help those in need. That is why since 1998 we have committed approximately $1.4 billion for compensating and assisting people infected or affected with hepatitis C. Of this amount, our government has allocated $875 million to a trust fund that is fulfilling our financial obligations to victims under the 1986 to 1990 hepatitis C settlement agreement.
When added to the funds contributed by the provinces and territories, financial assistance in the amount of $1.1 billion to thousands of victims was announced. By working collaboratively and collectively with provincial and territorial governments and the lawyers for the class action plaintiffs, we were able to reach a settlement agreement that was approved by the Superior Court of Justice of Ontario, the Supreme Court of British Columbia and the Cour Supérieure du Québec.
This agreement is administered by a third party appointed by the courts. As of October 1, 2004 approximately $387 million in benefits have been paid from the fund. However, it is important to remember that payments to beneficiaries may continue for up to 70 years to new claimants who have until 2010 to apply and for continuing payments to those who have already qualified. Therefore, no one should think the books are closed on those payments or on the response to the needs of these individuals.
That brings me to the situation of those Canadians who contracted hepatitis C prior to 1986 and after mid-1990 through the blood system. The federal government has been mindful of their plight and in response we have committed $525 million to a comprehensive hepatitis C package for Canadians. The largest portion of this money, some $300 million over 20 years, is going to the provinces and territories to ensure that people who contracted hepatitis C through the blood system outside the 1986 to 1990 period will have reasonable and ongoing access to appropriate hepatitis C treatment and care, such as drugs, immunizations and nursing care. The remainder was set aside to help track victims, for research and to enhance the safety of the blood supply to prevent future tragedies.
The possibility of a potential surplus in the trust fund used to compensate the 1986 to 1990 victims has led members of the House from all parties, advocacy groups and the media to ask whether such a surplus could be used to extend assistance to all hepatitis C victims, including those outside the 1986 to 1990 window.
Speculation about a surplus has been fuelled by the fact that the number of claimants anticipated in the 1986-1990 agreement has to date been lower than originally forecast, as well as the fact that advances in treatment have reduced the number of claimants requiring additional assistance.
I am pleased to reiterate to hon. members that our government is open to looking at the idea of using a potential actuarial surplus to assist claimants outside the 1986-1990 window. During the June election campaign the Prime Minister publicly stated that he was open to this idea. I have said as much both inside and outside the House.
However, it is very important to remember three salient facts. First, it is critical that the existence of a surplus in the fund is assessed and validated given that, as I mentioned earlier, there continue to be new claimants and the fund must have resources available to support beneficiaries over their lifetime. Second, the trust fund does not belong to the government. It belongs to the beneficiaries of trust subject to the court's discretion. Third, it will be up to the courts and the courts alone to determine whether a surplus exists. This determination will be made in June 2005.
A decision to share the trust fund would require the agreement of the current beneficiaries, their lawyers, along with the provinces and territories, as well as the courts. I want to make it clear that the cabinet is considering this issue. We are assessing the facts, the potential of changed circumstances, and our options for proceeding, because proceed we must.
We are mindful of the recent unanimous resolution of the Standing Committee on Health which called for compensation outside the 1986-1990 window. We also need and welcome the input of all parliamentarians because that would provide us with wisdom, experience and knowledge so that we can proceed further.